Growth inhibitory efficacy of the nutritional herb <em>Psoralea corylifolia</em> in a model of triple‑negative breast cancer

Telang,Nitin T.; Nair,Hareesh B.; Wong,George Y.C.

doi:10.3892/ijfn.2021.18

Growth inhibitory efficacy of the nutritional herb Psoralea corylifolia in a model of triple‑negative breast cancer

Authors:
- Nitin T. Telang
- Hareesh B. Nair
- George Y.C. Wong
View Affiliations

Affiliations: Cancer Prevention Research Program, Palindrome Liaisons Consultants, Montvale, NJ 07645‑1559, USA, Department of Obstetrics and Gynecology, University of Texas Health Sciences Center, San Antonio, TX 78229, USA, American Foundation for Chinese Medicine, New York, NY 10001, USA
Published online on: July 7, 2021 https://doi.org/10.3892/ijfn.2021.18
Article Number: 8
Copyright: © Telang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple‑negative breast cancer (TNBC) lacks the expression of estrogen receptor‑α (ER‑α), progesterone receptor (PR) and amplified human epidermal growth factor receptor‑2 (HER‑2). Current treatments involve chemotherapy and molecular targeted therapy. These options lead to dose‑limiting systemic toxicity and acquired tumor resistance. Moreover, no drug is yet available for the secondary prevention of TNBC. Such limitations underscore a need to investigate non‑toxic testable alternatives for the secondary prevention/treatment of TNBC. The Chinese nutritional herb, Psoralea corylifolia (PC), has been shown to be effective against the MCF‑7 cell line, a cellular model for ER‑α‑positive breast cancer. The present study aimed to investigate the growth inhibitory effects of PC against TNBC using the MDA‑MB‑231 cell line. Anchorage‑independent colony formation, cell cycle progression, cellular apoptosis, RB signaling and caspase‑3/7 activity assays were performed to determine the quantitative parameters for the efficacy of PC. Treatment with PC induced a 3.5‑fold increase in the G₁: S + G₂/M ratio, an 11‑fold increase in the apoptotic cell number and a 149‑fold increase in caspase‑3/7 activity. PC treatment also decreased cyclin D1, CDK4/6 and p‑RB expression levels. On the whole, the data of the present study identify mechanistic leads for PC as a naturally occurring testable alternative, and validate a mechanistic approach to prioritize efficacious nontoxic herbal extracts as nutritional supplements for the secondary prevention/therapy of TNBC.

View Figures

View References

1	Dinh P, Sotiriou C and Piccart MJ: The evolution of treatment strategies: Aiming at the target. Breast. 16 (Suppl 2):S10–S16. 2007.PubMed/NCBI View Article : Google Scholar
2	Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW and Carey LA: Poly(ADP-Ribose) polymerase inhibition: ‘targeted’ therapy for triple-negative breast cancer. Clin Cancer Res. 16:4702–4710. 2010.PubMed/NCBI View Article : Google Scholar
3	Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, et al: PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2:1036–1047. 2012.PubMed/NCBI View Article : Google Scholar
4	Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.PubMed/NCBI View Article : Google Scholar
5	Neergheen VS, Bahorun T, Taylor EW, Jen LS and Aruoma OI: Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemo-prevention. Toxicology. 278:229–241. 2010.PubMed/NCBI View Article : Google Scholar
6	Ye L, Jia Y, Ji KE, Sanders AJ, Xue K, Ji J, Mason MD and Jiang WG: Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis. Oncol Lett. 10:1240–1250. 2015.PubMed/NCBI View Article : Google Scholar
7	Telang N, Li G, Katdare M, Sepkovic D, Bradlow L and Wong G: Inhibitory effects of Chinese nutritional herbs in isogenic breast carcinoma cells with modulated estrogen receptor function. Oncol Lett. 12:3949–3957. 2016.PubMed/NCBI View Article : Google Scholar
8	Telang NT, Li G, Katdare M, Sepkovic DW, Bradlow HL and Wong GYC: The nutritional herb Epimedium grandiflorum inhibits the growth in a model for the Luminal A molecular subtype of breast cancer. Oncol Lett. 13:2477–2482. 2017.PubMed/NCBI View Article : Google Scholar
9	Telang N, Nair HB and Wong GYC: Efficacy of Dipsacus asperoides (DA) in a model for triple negative breast cancer. Cancer Res. 77 (Suppl 4):Abstract nr P4-13-04. 2017.
10	Telang NT, Nair HB and Wong GYC: Growth inhibitory efficacy of Cornus officinalis in a cell culture model for triple-negative breast cancer. Oncol Lett. 17:5261–5266. 2019.PubMed/NCBI View Article : Google Scholar
11	Bosco EE and Knudsen ES: RB in breast cancer: At the crossroads of tumorigenesis and treatment. Cell Cycle. 6:667–671. 2007.PubMed/NCBI View Article : Google Scholar
12	Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe J-P, Tong F, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515–527. 2006.PubMed/NCBI View Article : Google Scholar
13	Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG, et al: The expression patterns of ER, PR, HER-2, CK5/6, EGFR, Ki 67, and AR by immune-histochemical analysis in breast cancer cell lines. Breast Cancer (Auckl). 4:35–41. 2010.PubMed/NCBIErratum in: Breast Cancer (Auckl) 12: 1178223418806626, 2018.
14	Khushboo PS, Jadhav VM, Kadam VJ and Sathe NS: Psoralea corylifolia Linn. - ‘Kushtanashini’. Pharmacogn Rev. 4:69–76. 2010.PubMed/NCBI View Article : Google Scholar
15	Telang N: Anti-proliferative and pro-apoptotic effects of rosemary and constituent terpenoids in a model for the HER-2-enriched molecular subtype of clinical breast cancer. Oncol Lett. 16:5489–5497. 2018.PubMed/NCBI View Article : Google Scholar
16	Burkhart DL and Sage J: Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 8:671–682. 2008.PubMed/NCBI View Article : Google Scholar
17	Musgrove EA, Caldon CE, Barraclough J, Stone A and Sutherland RL: Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 11:558–572. 2011.PubMed/NCBI View Article : Google Scholar
18	Sherr CJ and Roberts JM: CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512. 1999.PubMed/NCBI View Article : Google Scholar
19	Zhang X, Zhao W, Wang Y, Lu J and Chen X: The chemical constituents and bioactivities of Psoralia corylifolia Linn.: A Review. Am J Chin Med. 44:35–60. 2016.PubMed/NCBI View Article : Google Scholar
20	Shi J, Chen Y, Chen W, Tang C, Zhang H, Chen Y, Yang X, Xu Z, Wei J and Chen J: Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells. J Cell Mol Med. 22:5220–5230. 2018.PubMed/NCBI View Article : Google Scholar
21	Li Y, Qin X, Li P, Zhang H, Lin T, Miao Z and Ma S: Isobavachalcone isolated from Psoralia corylifolia inhibits cell proliferation and induces apoptosis via inhibiting AKT/GSK-3β/β-catenin pathway. Drug Des Devel Ther. 13:1449–1460. 2019.PubMed/NCBI View Article : Google Scholar
22	Park GH, Sung JH, Song HM and Jeong JB: Anti-cancer activity of Psoralea fructus through the downregulation of cyclin D1 and CDK4 in human colorectal cancer cells. BMC Complement Altern Med. 16(373)2016.PubMed/NCBI View Article : Google Scholar
23	Rajan V, Tripathi J, Variyar P and Pandey BN: Mechanism of cytotoxicity by Psoralea corylifolia extract in human breast carcinoma cells. J Environ Pathol Toxicol Oncol. 33:265–277. 2014.PubMed/NCBI View Article : Google Scholar
24	Wang X, Cheng K, Han Y, Zhang G, Dong J, Cui Y and Yang Z: Effect of Psoralen as an anti-tumor agent in human breast cancer MCF-7/ADR cells. Biol Pharm Bull. 39:815–822. 2016.PubMed/NCBI View Article : Google Scholar